triple glp-1/gip/glucagon receptor agonist Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Science Behind GLP 1 GIP

The triple agonist approach creates what researchers describe as a metabolic triple threat

Editorial standards At Noom, were committed to providing health information thats grounded in reliable science and expert review

Seino Y, Yabe D, Sasaki T, et al

doi: 10.1056/NEJMoa1611925

Although GLP-1R expression in peripheral tissues is generally low and restricted to rare cell types (26), antiinflammatory benefits have been observed in various preclinical models, such as obesity, atherosclerosis, steatohepatitis, and nephritis, even in the absence of direct immune cell targeting (2732)

The central role of these pathways in both conditions might explain the dual potential of GLP-1RAs to either worsen or improve disease progression based on the individual patients immune response and metabolic status